This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
The worst of the pandemic may be behind us, but COVID-19 remains a serious risk for chronic lymphocytic patients and likely will be for some time to come.
By following CLL Society’s Recommendations for COVID-19 Vaccinated Chronic Lymphocytic Leukemia (CLL) Patients Based on the CDC Updated Considerations for People who are Immunocompromised and on the Underlying Data odds are very good one will never need these Checklists, but it is always best to plan ahead.
Vaccines and even masks and social distancing, though excellent at slowing the spread of the SARS-CoV-2 virus, will never be 100% protective for everyone, especially the immune-compromised.
This is another reason that it is very important to have as part of your plan knowing exactly where you can go to receive monoclonal antibody therapy for COVID-19. Monoclonal antibodies must be received within 10 days of infection (and for those with CLL, receive asap after known exposure). Search this map to find locations near you that have monoclonal antibody therapy available.
The time to prepare for exposure and even infection is now, not post-exposure or when diagnosed with COVID-19. In the worst case, illness and fear can cloud judgment when one might need to be at their best, thinking clearly and acting quickly.
These simple checklists should be completed, printed out in advance, and stored in an easily accessible place.
This should minimize most last-minute scrambles for documents and any hurried search for appropriate healthcare with the expertise and access to the best possible treatments such as monoclonal antibodies that are tailored to the needs of an immunocompromised CLL patient.
Print, complete, and put aside these five documents:
We hope you never need them. But complete them now just in case.
Stay strong, we are all in the together.
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.